Optimizing the cell therapy patient journey through integrated CRO/CDMO partnership
Sponsor
Live30 webinars are thirty-minute presentations designed to update you on the latest innovations, applications, and data in a fast yet interactive format.
Cell therapies represent an exciting new treatment paradigm for patients, with multiple global approvals expected in the coming years. As with any new and emerging therapy, patient challenges and operating model complexities still require further optimization to improve accessibility. Some specific obstacles for cell therapy clinical trials include a limited number of qualified sites, meeting patient recruitment targets, complex care needs and potential adverse events, logistics/travel requirements, and more. Manufacturing also continues to be one of the major bottlenecks to more widespread adoption of cell therapies globally and a major contribution to high treatment costs. Difficulties achieving commercial scale, labor-intensive processes due to lack of standardization/automation, and complex supply chain needs are all examples of current challenges that have yet to be fully addressed.
Patient journey mapping is a critical strategy to better understand the key touchpoints that provide opportunities for improvements, many of which can be influenced by CRO and CDMO organizations. Working with a single integrated partner can help ease industry challenges and provide an accelerated path from development to manufacturing, as well as the benefits that come from unified teams and infrastructure.
In this webinar, we will provide insights on the cell therapy patient experience and the role of a CRO/CDMO partner in optimizing that journey through effective collaboration and end-to-end integrated solutions for development, manufacturing, and distribution.
- Overview of patient mapping approach to better understand the patient journey and identify areas for enhanced efficiencies
- Insights into complexities of the cell therapy ecosystem and specific challenges that must be overcome to successfully move therapies from bench to bedside
- Opportunities to leverage an integrated partner to streamline cell therapy development and mitigate risks related to manufacturing, regulatory compliance, and commercialization
- Real-world case study demonstrating improvement of patient experience
SPEAKERS
You might also like
Mastering the journey from initial method transfer to successful lot release for cell & gene therapies
Positioning early cell therapy programs for clinical success: insights to mitigate risk and ensure GMP readiness
Evaluation and performance of an AAV affinity resin: a CDMO case study
Assessing CAR-T cell therapy in vitro using patient-derived glioblastoma organoids
